Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.

about

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.

Item

http://www.wikidata.org/entity/Q47192515

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.

@en

type

Item

label

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.

@en

prefLabel

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.

@en

P1476

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.

@en

P2093

Maurie Markman

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

P304

1745505717750694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1177/1745505717750694

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29313444

http://www.w3.org/2001/XMLSchema#string

P921

ovarian neoplasm

ovarian cancer

mechanism of action

P932

5784554

http://www.w3.org/2001/XMLSchema#string